Deerfield Management Company, L.P. (Series C) Kymera Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 593,000 shares of KYMR stock, worth $24.5 Million. This represents 0.41% of its overall portfolio holdings.
Number of Shares
593,000
Previous 593,000
-0.0%
Holding current value
$24.5 Million
Previous $23.9 Million
31.97%
% of portfolio
0.41%
Previous 0.59%
Shares
1 transactions
Others Institutions Holding KYMR
# of Institutions
180Shares Held
67.6MCall Options Held
223KPut Options Held
241K-
Price T Rowe Associates Inc Baltimore, MD6.7MShares$277 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.46MShares$267 Million2.86% of portfolio
-
Wellington Management Group LLP Boston, MA6MShares$248 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$248 Million1.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.23MShares$216 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.26B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...